Botanix Pharmaceuticals Ltd (BOT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has a cash flow conversion efficiency ratio of -0.591x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-48.02 Million) by net assets (AU$81.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Botanix Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Botanix Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cassiar Gold Corp
V:GLDC
|
-0.247x |
|
Pan Brothers Tbk
JK:PBRX
|
0.059x |
|
AdVini S.A.
PA:ALAVI
|
0.103x |
|
Rumble Resources Ltd
AU:RTR
|
-0.030x |
|
Cheil Grinding
KO:001560
|
0.025x |
|
Asia Medical & Agricultural Laboratory & Research Center PCL
BK:AMARC
|
0.085x |
|
HORNG SHIUE HOLDING Co Ltd
TW:2243
|
-0.071x |
|
Santova Ltd
JSE:SNV
|
0.078x |
Annual Cash Flow Conversion Efficiency for Botanix Pharmaceuticals Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Botanix Pharmaceuticals Ltd from 1991 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$81.30 Million | AU$-78.58 Million | -0.967x | -1193.21% |
| 2024-06-30 | AU$108.73 Million | AU$-8.13 Million | -0.075x | +85.79% |
| 2023-06-30 | AU$22.95 Million | AU$-12.07 Million | -0.526x | +61.66% |
| 2022-06-30 | AU$8.15 Million | AU$-11.18 Million | -1.372x | -861.49% |
| 2021-06-30 | AU$20.80 Million | AU$-2.97 Million | -0.143x | +80.57% |
| 2020-06-30 | AU$23.64 Million | AU$-17.36 Million | -0.734x | +96.56% |
| 2019-06-30 | AU$615.22K | AU$-13.14 Million | -21.360x | -3410.32% |
| 2018-06-30 | AU$16.28 Million | AU$-9.91 Million | -0.608x | +28.70% |
| 2017-06-30 | AU$5.44 Million | AU$-4.64 Million | -0.853x | -40490.24% |
| 2016-06-30 | AU$3.18 Million | AU$-6.69K | -0.002x | +99.79% |
| 2015-06-30 | AU$1.23 Million | AU$-1.20 Million | -0.980x | -70.31% |
| 2014-06-30 | AU$2.24 Million | AU$-1.29 Million | -0.575x | -238.34% |
| 2013-06-30 | AU$-2.50 Million | AU$-1.04 Million | 0.416x | -13.19% |
| 2012-06-30 | AU$-2.33 Million | AU$-1.12 Million | 0.479x | +54.21% |
| 2011-06-30 | AU$-2.23 Million | AU$-692.97K | 0.311x | -35.20% |
| 2010-06-30 | AU$-1.80 Million | AU$-861.12K | 0.479x | +125.99% |
| 2009-06-30 | AU$877.74K | AU$-1.62 Million | -1.844x | +0.15% |
| 2008-06-30 | AU$1.29 Million | AU$-2.38 Million | -1.847x | -94.45% |
| 2007-06-30 | AU$2.90 Million | AU$-2.75 Million | -0.950x | +29.94% |
| 2006-06-30 | AU$2.22 Million | AU$-3.01 Million | -1.356x | -64.76% |
| 2005-06-30 | AU$3.46 Million | AU$-2.84 Million | -0.823x | -213.18% |
| 2004-06-30 | AU$2.24 Million | AU$-589.68K | -0.263x | +9.32% |
| 2002-06-30 | AU$4.05 Million | AU$-1.17 Million | -0.290x | -395.90% |
| 2001-06-30 | AU$5.69 Million | AU$-332.70K | -0.058x | +80.44% |
| 2000-06-30 | AU$5.15 Million | AU$-1.54 Million | -0.299x | +45.25% |
| 1999-06-30 | AU$8.08 Million | AU$-4.41 Million | -0.546x | -218.85% |
| 1998-06-30 | AU$15.75 Million | AU$7.23 Million | 0.459x | +547.35% |
| 1997-06-30 | AU$32.05 Million | AU$-3.29 Million | -0.103x | -8556.45% |
| 1996-06-30 | AU$37.91 Million | AU$46.00K | 0.001x | -99.25% |
| 1995-06-30 | AU$38.44 Million | AU$6.24 Million | 0.162x | +68.58% |
| 1994-06-30 | AU$26.04 Million | AU$2.51 Million | 0.096x | +25.35% |
| 1993-06-30 | AU$18.35 Million | AU$1.41 Million | 0.077x | -39.42% |
| 1992-06-30 | AU$11.41 Million | AU$1.45 Million | 0.127x | -15.46% |
| 1991-06-30 | AU$12.88 Million | AU$1.93 Million | 0.150x | -- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more